<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nomogram for adjusting unfractionated heparin in adults using anti-factor Xa activity &lt;em&gt;or&lt;/em&gt;* the aPTT</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nomogram for adjusting unfractionated heparin in adults using anti-factor Xa activity <em>or</em>* the aPTT</h1>
<div class="graphic"><div class="figure"><div class="ttl">Nomogram for adjusting unfractionated heparin in adults using anti-factor Xa activity <em>or</em>* the aPTT</div><div class="cntnt"><table cellspacing="0"><colgroup width="25%"></colgroup> <colgroup width="50%"></colgroup> <colgroup width="25%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="centered" colspan="3"> <p><strong>Bolus:</strong> 80 units/kg (using total body weight)</p> <strong>Maximum</strong> = 10,000 units</td> </tr> <tr class="divider_bottom"> <td class="centered" colspan="3"> <p><strong>Initial infusion rate:</strong> 18 units/kg/hr (using total body weight)</p> <strong>Maximum</strong> = 2000 units/hour</td> </tr> <tr> <td class="subtitle1_left">If using anti-factor Xa activity*<br/> (IU/mL)</td> <td class="subtitle1_left">Response</td> <td class="subtitle1_left">If using aPTT*<br/> (seconds)<sup>¶</sup></td> </tr> <tr> <td>0.00 to 0.09</td> <td> <ul> <li>Bolus 25 units/kg</li> <li>Increase infusion by 3 units/kg/hour</li> <li>Repeat assay in 6 hours</li> </ul> </td> <td>&lt;40</td> </tr> <tr> <td>0.10 to 0.19</td> <td> <ul> <li>Increase infusion by 2 units/kg/hour</li> <li>Repeat assay in 6 hours</li> </ul> </td> <td>40 to 49</td> </tr> <tr> <td>0.20 to 0.29</td> <td> <ul> <li>Increase infusion by 1 unit/kg/hour</li> <li>Repeat assay in 6 hours</li> </ul> </td> <td>50 to 69</td> </tr> <tr> <td>0.30 to 0.7</td> <td> <ul> <li>NO CHANGE (within therapeutic range)</li> <li>Repeat assay in 6 hours</li> <li>Once therapeutic for two assays, may change to once daily assays</li> </ul> </td> <td>70 to 110<sup>¶</sup></td> </tr> <tr> <td>0.71 to 0.79</td> <td> <ul> <li>Decrease infusion by 1 unit/kg/hour</li> <li>Repeat assay in 6 hours</li> </ul> </td> <td>111 to 120</td> </tr> <tr> <td>0.80 to 0.89</td> <td> <ul> <li>STOP INFUSION for 1 hour, then decrease by 2 units/kg/hour</li> <li>Repeat assay 6 hours after restarting the infusion</li> </ul> </td> <td>121 to 130</td> </tr> <tr> <td>0.90 to 0.99</td> <td> <ul> <li>STOP INFUSION for 1 hour, then decrease by 3 units/kg/hr</li> <li>Repeat assay 6 hours after restarting the infusion</li> </ul> </td> <td>131 to 140</td> </tr> <tr> <td>1.00 to 1.09</td> <td> <ul> <li>STOP INFUSION for 2 hours, then decrease by 4 units/kg/hr</li> <li>Repeat assay 6 hours after restarting the infusion</li> </ul> </td> <td>141 to 150</td> </tr> <tr> <td>≥1.10</td> <td> <ul> <li>STOP INFUSION for 2 hours, then decrease by 5 units/kg/hr and notify clinician</li> <li>Repeat assay 6 hours after restarting the infusion</li> </ul> </td> <td>&gt;150</td> </tr> </tbody></table></div><div class="graphic_lgnd">This is one example of a weight-based heparin dosing nomogram using either anti-factor Xa activity <strong>or</strong> aPTT for therapeutic heparin dosing (eg, for acute VTE). Only one measure should be used (anti-factor Xa or aPTT); they are rarely concordant. All doses are based on actual body weight in kilograms. The initial and subsequent bolus doses, infusion rate changes, and dosing intensity based on the indication for unfractionated heparin (eg, VTE, stroke, acute coronary syndrome) should be established separately for each institution. Refer to UpToDate for additional details.</div><div class="graphic_footnotes"><p>aPTT: activated partial thromboplastin time; VTE: venous thromboembolism; IU: international units.</p>
<p>* Only one measurement (the anti-factor Xa activity level <strong>or</strong> the aPTT) should be used; they are rarely concordant. If aPTT is used to adjust
    heparin, check with your laboratory to determine the aPTT values (in seconds)
    that would correspond to the anti-factor Xa values in this table.</p>
    
    ¶ The therapeutic ranges for the aPTT (corresponding to an anti-factor Xa activity of 0.3 to 0.7 IU/mL) are dependent on local reagents and instrumentation and must be established by each individual institution.</div><div class="graphic_reference">Courtesy of Allison E Burnett, PharmD, PhC, CACP.</div><div id="graphicVersion">Graphic 122945 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
